NLRP3-IN-41 

NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research^[1].

NLRP3-IN-41 (5-15 μM, 24 h) significantly inhibits LPS (100 ng/mL) and ATP(5 mM) induced IL-1βin THP-M and inhibits the AIM2 and NLRC4 inflammasome^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NLRP3-IN-41 (40, 80 mg/kg, i.g., 10 days) attenuates the symptoms of DSS-induced colitis in C57BL/6 and ICR mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

442.55

C₂₂H₂₂N₂O₄S₂

1209698-02-1

O=S(N1CCCC2=CC=C(C=C21)NS(=O)(C3=CC=C(C=C3)C4=CC=CC=C4)=O)(C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang F, et al. Identification and Validation of PKR as a Direct Target for the Novel Sulfonamide-Substituted Tetrahydroquinoline Nonselective Inhibitor of the NLRP3 Inflammasome. J Med Chem. 2024 Jun 10.  [Content Brief]